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Introduction
Acute myeloid leukemia (AML) comprises a genetically and clinically heterogeneous group of aggressive hematological neoplasms. 1 Continuing research into the pathogenesis and heterogeneity of AML has resulted in the development of several potentially useful therapeutic agents. 2 However, despite some advances in the treatment of AML, therapies have not changed significantly in the past 20 years.
Further research is thus warranted to identify effective agents and develop new therapeutic strategies for the treatment of this deadly disease. Flavonoids possess diverse biological and pharmaceutical properties and have been subjected to extensive investigations as likely candidates for cancer treatment. 3 Scutellaria baicalensis Georgi (Huang Qin) is one of the most popular and multi-purpose traditional Chinese medicinal herbs, and has a high flavonoid content. 4 Wogonin, a flavonoid extracted from S. baicalensis, has several biological effects including antioxidant, antiinflammatory, antiviral, neuroprotective, anxiolytic and anticancer activities. 5 It has been shown to possess anti-tumor effects in various cancer cells, 6 including anti-proliferation, cell cycle arrest, induction of apoptosis and differentiation, inhibition of angiogenesis, anti-invasion, and increased sensitivity to apoptosis. Moreover, wogonin has shown therapeutic potential for the treatment of hematologic malignancies. 7 Flavonoid aglycones undergo rapid and extensive metabolism after either oral or intravenous administration. Flavonoid aglycones enter the bloodstream in the form of glucuronide or sulfate conjugates, and very little unchanged aglycone can be found in the plasma, while levels of glucuronic acid
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From 4 conjugates are high. Glucuronidation is thought to affect the biological activity of aglycones by altering the physico-chemical properties of flavonoids, which is seen as a detoxification process. The biological activities of these conjugates are thus important. 8, 9 The flavonoid wogonoside can also be derived from S. baicalensis, meanwhile it is a metabolite of wogonin. It is known to possess anti-inflammatory 10 and anti-inflammation-induced angiogenic activities; 11 however, its anti-leukemic properties have not been explored.
Phospholipid scramblase 1 (PLSCR1) was originally identified as a type II transmembrane protein that mediates the calcium-dependent bidirectional movement of membrane phospholipids, and as a substrate for several kinases that participate in kinase signaling pathways, including c-Abl, c-Src, and protein kinase Cδ (PKCδ). 12 Furthermore, PLSCR1 plays potential roles in hematopoiesis and leukemogenesis.
PLSCR1
-/-bone marrow cells exhibit defective myeloid proliferation and differentiation in response to stimulation by selected growth factors. 13 Moreover, MmTRA1b/PLSCR1 mRNA levels correlate with significantly longer overall survival in AML, and PLSCR1 gene expression has been identified as a new prognostic factor in AML. 14 PLSCR1 generally plays an antagonistic role in leukemia development. We previously found that wogonin induced granulocytic differentiation and up-regulated PLSCR1 gene expression in NB4 cells. 15 PLSCR1 also trafficked into the nucleus, and may thus have a possible additional nuclear function. However, the ability of wogonoside to induce the differentiation of AML cells and promote the function of PLSCR1 requires further investigation.
The present study investigated the anti-proliferative activity of wogonoside in vitro and in vivo, and also examined its effects on cell cycle progression and 
Materials and Methods

Compounds and reagents
Wogonoside (>98% purity, Langze Pharmaceutical Co., Ltd., Nanjing, China), all-trans retinoic acid (ATRA) and phorbol myristate acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA) were dissolved in dimethyl sulfoxide (DMSO) as stock solutions at 0.5 M, 20 mM and 1.6 mM, respectively. All stock solutions were stored at −20 °C. PLSCR1 small interfering RNA (siRNA) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and transfection was performed using
Lipofectamine 2000
TM reagent (Invitrogen, San Diego, CA, USA), according to the manufacturer's instructions. 16 The nuclear/cytosol fractionation kit (KeyGEN, Nanjing, China) was used according to the manufacturer's directions.
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Cell cycle and differentiation analyses
The cell cycle was analyzed by propidium iodide (PI) staining and using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA). 22 The percentage of cells in each phase of the cell cycle was quantitated with ModFit 
Western blot analysis
Western blot analysis was performed as described previously. 26 (For more details, see supplemental Methods). Detection was performed using the Odyssey Infrared
Imaging System (LI-COR Inc., Lincoln, NE, USA.).
Immunofluorescence microscopy
Subcellular localization of PLSCR1 was analyzed by immunofluorescence microscopy as described previously. 27 (For more details, see supplemental Methods).
Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR)
For quantitative analysis of gene expression, total RNA was isolated using a Trizol kit (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using a cDNA synthesis kit Data were analyzed using 7500 system SDS software.
Electrophoretic mobility shift assay (EMSA)
Preparation of nuclear extracts and electrophoretic mobility shift assays were conducted according to the manufacturer's instructions (Beyotime EMSA Kit, NanJing, China). 30 (For more details, see supplemental Methods).
Statistical analysis
All data were expressed as mean ± S.E.M. The data shown were obtained from at least three independent experiments. Statistical analysis of multiple-group comparisons was performed by one-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test. Comparisons between two groups were analyzed using 2-tailed Student's t-tests. Survival of NOD/SCID mice was evaluated by Kaplan-Meier analysis using log-rank test to compare the difference. A P value < 0.05 was considered statistically significant. 
Results
Anti-proliferative effects of wogonoside in vitro and in vivo
The anti-proliferative effects of wogonoside in U937 and HL-60 cells and primary AML cells were examined by trypan blue dye exclusion ( Figure 1A and 1B) .
Wogonoside inhibited growth of these cells. The anti-proliferative activity of wogonoside was further evaluated by soft agar colony-formation assay. Colony number and colony size were reduced in U937 and HL-60 cells treated with wogonoside compared with controls ( Figure 1C) . Moreover, the ability of wogonoside to inhibit the growth of U937 cells in vivo was investigated using a female nude mouse xenograft model ( Figure 1D For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From
Effect of wogonoside on cell cycle progression
We examined the effect of wogonoside on cell cycle progression in U937 and HL-60 cells. Wogonoside arrested cell cycle at G0/G1 phase and decreased G2/M and S phases in both cell lines in a dose-dependent manner (Figure 2A and 2B). To further investigate the molecules affected by wogonoside, we examined the expression levels of several G0/G1 to S phase-transition-related proteins under the same conditions. Cyclin-dependent kinase (CDK) 4 and cyclin D1 appear to be necessary for transition through early G1 phase, whereas CDK2, cyclin E and cyclin A are necessary for the completion of G1 phase and initiation of S phase. 31 Wogonoside down-regulated CDK4 and cyclin D1 protein levels, but had little effect on CDK2, cyclin A, and cyclin E levels in both cell lines ( Figure 2C ). Meanwhile, expression of the CDK4 inhibitor p16 (INK4A) protein was increased by wogonoside treatment. These results indicate that wogonoside could induce G0/G1 cell cycle arrest in human AML cells. Figure 4C ), suggesting that the elevated PLSCR1 protein levels in U937 and HL-60 cells exposed to wogonoside were the result of transcriptional activation. We also analyzed some critical cell cycle-and differentiation-related genes regulated by PLSCR1, including p21waf1⁄cip1 and c-Myc. Induction of PLSCR1 expression has been reported to increase p21waf1⁄cip1 protein by increasing transcription and reducing degradation, and to significantly inhibit c-Myc mRNA and protein expression. 32 We similarly observed downregulation of c-Myc in U937 and HL-60 cells from 24 h after exposure to wogonoside. p21waf1⁄cip1 was increased approximately 48 h after wogonoside treatment in U937 and HL-60 cells ( Figure 4D ).
Differentiation-inducing capacity of wogonoside
The wogonoside-induced changes in c-Myc, p21waf1⁄cip1 and PLSCR1 observed in the current study were in accord with the results of previous research.
32
Wogonoside promotes PLSCR1 transport into the nucleus and facilitates its binding to the inositol 1, 4, 5-trisphosphate receptor 1 (IP3R1) promoter
In addition to the biological function of PLSCR1 at the plasma membrane and cytoplasm, recent results have suggested that this protein plays an additional role in the nucleus by binding to genomic DNA. 33 In order to understand the subcellular distribution of PLSCR1 after induction by wogonoside, we fractionated nuclei and cytoplasm/membrane proteins in the presence of wogonoside for 0, 24, 48, 72 and 96
h. Western blot analyses of fractionated cells showed that nuclear PLSCR1 was scarcely detectable before treatment, but nuclear localization increased after treatment with wogonoside ( Figure 5A ). Nuclear localization of PLSCR1 by wogonoside was confirmed by immunofluorescence analysis. PLSCR1 antigen was detected using fluorescein isothiocyanate (FITC)-labeled secondary antibody (green channel), and nuclear DNA was stained with DAPI (blue channel). PLSCR1 trafficking into the nucleus was observed following treatment with wogonoside for 48 h ( Figure 5B ).
For personal use only. on May 30, 2017 . by guest www.bloodjournal.org From 13 PLSCR1 was previously reported to traffic into the nucleus and bind to a specific segment of the IP3R1 5'-promoter and enhance transcription of this gene. 34 We therefore investigated the promotion of PLSCR1 binding to the IP3R1 gene promoter by wogonoside using EMSA. PLSCR1 binding to double-stranded oligonucleotides containing the IP3R1 promoter was up-regulated after treatment with 150
μ M wogonoside for 48 h, while untreated cells showed little or no DNA binding in the promoter ( Figure 5C ). It is also noted that IP3R1 expression increased in U937 and HL-60 cells exposed to 150 μ M wogonoside. (Figure 5D ). These studies revealed that wogonoside promoted PLSCR1 translocation into the nucleus, and suggest that wogonoside may augment the biological functions of PLSCR1 in the nucleus.
PLSCR1 is required for wogonoside-induced cell cycle arrest and differentiation
To determine the role of PLSCR1 in wogonoside-induced cell cycle arrest and differentiation, U937 and HL-60 cells were transfected with siRNA against PLSCR1.
The efficacy of siRNA to inhibit PLSCR1 is shown in Figure 6A . After transfection, wogonoside-induced G0/G1 phase arrest was decreased as observed previously ( Figure 6B ). Compared with non-specific RNA groups, NBT-reducing activity in U937 and HL-60 cells ( Figure 6C ) and CD11b/CD14 expression in U937 cells ( Figure   6D ) were decreased in PLSCR1 siRNA groups after wogonoside treatment. To p21waf1⁄cip1 is not only an negative regulator of G1-phase cell cycle progression, but is also involved in the regulation of progression to terminal differentiation. 38 The oncogenic protein c-Myc elicits a variety of biological responses related to cell cycle distribution, differentiation, and apoptosis, and is frequently activated in AML and plays an important role in the induction of leukemogenesis. 39, 40 To gain further insight into the wogonoside-induced events leading to G0/G1 arrest during terminal 33 In the absence of palmitoylation, PLSCR1 import into the nucleus is mediated by the importin α /β nucleopore transport system, where it binds to DNA. 42 PLSCR1 within the nucleus is involved in responding to cytokine induction and precursor maturation. PLSCR1 has been shown to traffic into the nucleus in the human ovarian tumor cell line HEY1B in response to IFN induction. 41 Nuclear-localized PLSCR1 enhanced granulopoiesis in mice stimulated by granulocyte-colony stimulating factor, resulting in the production of neutrophils from hematopoietic precursors and leading to an increase in the number of mature blood neutrophils. 43 In the present study, PLSCR1 was found inside the nucleus in U937 and ), enhancing transcription of this gene. 34 IP3R1 is known to play a key role in IP3-mediated mobilization of intracellular Ca 2+ stores from the endoplasmic reticulum in a variety of cells and tissues, and is also essential for cell growth and differentiation. 44, 45 IP3R1 expression in many cells is up-regulated in response to ATRA, DMSO, and interleukin-1β. [46] [47] [48] The effects of PLSCR1 on cell proliferation and maturation may also be related to alterations in the expression of cellular IP3R1. 49 The results showed that wogonoside promoted nuclear PLSCR1 binding to the transcriptional activation 
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